Maternal Serum Delta-Like 1 and Nesfatin-1 Levels in Gestational Diabetes Mellitus: A Prospective Case-Control Study

Objective Delta-like 1 (DLK1) and nesfatin-1 are adipokines that have been shown to affect glucose metabolism. We aimed to search serum DLK1 and nesfatin-1 concentrations at 24-28 weeks of pregnancy in women newly defined with gestational diabetes mellitus (GDM) and investigate the relationship of these adipokines with various metabolic parameters. Methods Serum levels of DLK1 and nesfatin-1 were evaluated in 44 women with GDM, and in 40 healthy pregnant women by enzyme-linked immunosorbent assay (ELISA) kiLs. While performing oral glucose tolerance Lest (OGTT) for GDM diagnosis at 24-28 weeks of pregnancy, homeostasis model assessment of insulin resistance (HOMA-IR), lipid profiles, glycosylated hemoglobin (HbA1c) were also measured. Results Maternal serum DLKI and nesfatin-1 concentrations were found lower in pregnant women with GDM compared with healthy pregnant women (418.4 +/- 282.6 vs. 586.7 +/- 303 ng/L, p=0.002; 12.2 +/- 7.6 vs. 26.7 +/- 16.4 ng/ml, p<0.001, respectively). Maternal serum DLK1 levels correlated positively with HOMA-1R and fasting insulin (r=0.395, p).008; r=0.374, p=0.012, respectively). Conclusion We determined that DLK1 and nesfatin-1 levels were lower in GDM. Based on this study, it may be considered that DLK1 could be culpable for metabolic disorders in GDM.